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Sputum analysis is increasingly used to assess airway inflammation in asthma. The analysis of sputum
is currently performed with two techniques, i.e., analysis of selected sputum (plugs) and analysis of
entire sputum. To investigate the diagnostic value of these two methods, we compared total and dif-
ferential cell counts and supernatant eosinophil cationic protein (ECP) in selected and entire sputum
collected on two occasions in a group of healthy and asthmatic subjects. We induced sputum with hy-
pertonic saline in 18 asthmatics and in eight healthy subjects. On one occasion we analyzed selected
sputum, and on another occasion we analyzed entire sputum. In each sample we measured total and
differential cell counts and ECP concentration in supernatant. We found a higher percentage of eosi-
nophils (15.3 versus 8.3%; p 
 
,
 
 0.01), more viable nonsquamous cells (80.6 versus 71.8%; p 
 
,
 
 0.01),
and higher levels of ECP (548 versus 105 
 
m
 
g/L; p 
 
,
 
 0.001) in selected sputum as compared with en-
tire sputum, whereas the percentage of neutrophils was higher in the entire sputum (42.7 versus
33.3%; p 
 
,
 
 0.05). The percentage of eosinophils and ECP concentration were significantly and simi-
larly increased in both selected and entire sputum of asthmatic subjects, i.e., independent of the
method of sputum analysis. In conclusion, the selected sputum method may indeed provide more vi-
able cells, more eosinophils, and a higher concentration of ECP. However, both the selected sputum
and the entire sputum method have the same diagnostic value in distinguishing asthmatics from
healthy subjects. 
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Sputum analysis is increasingly used to assess airway inflam-
mation in asthma (1, 2). The analysis of sputum is currently
performed with two techniques, i.e., analysis of selected spu-
tum and analysis of entire sputum. The first involves collecting
and analyzing the more viscid portions of mucus (plugs) ex-
tracted from entire sputum as described by Popov and col-
leagues (2). The second involves collecting and analyzing the
entire sputum, including saliva, as described by Fahy and col-
leagues (3). Both techniques have been shown to be valid, i.e.,
to distinguish between asthma and normal subjects, to detect
acute airway inflammation during allergen challenge, and to
detect reduced airway inflammation after treatment (1–6),
and reproducible (7–9).
To measure the diagnostic value of these two techniques, in
this study we compared these two methods of analysis of spu-
tum by measuring total and differential cell counts and super-
natant eosinophil cationic protein (ECP) in induced sputum
collected in normal and in asthmatic subjects. To our knowl-
edge this is the first study comparing total and differential cell
counts and ECP levels in induced sputum collected on two oc-
casions in the same subjects using two different techniques of
processing samples.
 
METHODS
 
Subjects
 
We studied 18 subjects with bronchial asthma and eight healthy sub-
jects (Table 1). Asthma was defined as a clinical history of intermit-
tent wheeze, cough, chest tightness, or dyspnea, and documented re-
versible airflow limitation with an improvement in FEV
 
1
 
 
 
>
 
 20% after
albuterol (200 
 
m
 
g) when FEV
 
1
 
 was 
 
<
 
 70% predicted or methacholine
airway responsiveness (PD
 
20
 
 
 
>
 
 1,600 
 
m
 
g) when FEV
 
1
 
 was 
 
>
 
 70% (10).
All subjects were stable as demonstrated by the low daily variability
(
 
,
 
 15%) of peak flow measurements during 2 wk before the study
(11). Medications were unchanged for at least 1 mo before the study,
except for inhaled 
 
b
 
2
 
-agonists taken as required. None referred a his-
tory of an upper respiratory infection in the preceding four wk.
Healthy subjects were nonsmokers with no history of asthma or
other respiratory symptoms, FEV
 
1
 
 
 
.
 
 80% predicted, and methacho-
line airway responsiveness PD
 
20
 
 
 
.
 
 1,600 
 
m
 
g. The study was approved
by the Ethics Committee of Fondazione Salvatore Maugeri, and all
subjects gave written informed consent.
 
Study Design
 
Subjects attended the laboratory on 3 d at the same time of the day.
On the first visit consent was obtained, subject characteristics were doc-
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umented by questionnaire, and skin prick tests and spirometry (Vita-
lograph, Buckinghamshire, UK) were performed. If spirometry showed
FEV
 
1
 
 
 
>
 
 70% a methacholine inhalation test was carried out, and the
results were expressed as the PD
 
20
 
 in noncumulative units; if FEV
 
1
 
< 
 
70%, reversibility of airway obstruction was performed using 200
 
m
 
g inhaled albuterol. On the second and third visits (24 h apart) the
sputum was induced after inhaled albuterol (200 
 
m
 
g) and was ana-
lyzed using two different methods: the selected sputum and the entire
sputum. Before the second visit the order in which the two methods
were performed was randomized in each subject. In a subset of eight
asthmatics sputum was induced on two other occasions, 24 h apart,
within 2 wk after the end of the study. The samples were analyzed
with the same technique (selected sputum) to show any possible influ-
ence of the first inhalation of hypertonic saline on the cellularity of
the second analysis.
 
Sputum Induction
 
FEV
 
1
 
 and FVC were measured before and 10 min after albuterol in-
halation (two puffs; 200 
 
m
 
g) and subjects then inhaled hypertonic
(4.5%) saline nebulized for increasing time periods, 1, 2, 4, 8, and 16
min, FEV
 
1
 
 was repeated 1 min after each inhalation period (12). Sa-
line solutions were nebulized by an ultrasonic nebulizer (DeVilbiss 65;
DeVilbiss Corp., Somerset, PA).
Collected sputum and saliva samples were examined within 2 h af-
ter the 16-min inhalation. The duration of inhalation of hypertonic sa-
line was the same (five inhalation times of 1 to 16 min) in each subject
on the two occasions.
 
Selected sputum.
 
Sputum was collected and processed using meth-
ods identical to those described by Popov and colleagues (2). Selected
portions (plugs) of the sputum sample originating from the lower re-
spiratory tract were chosen using an inverted microscope and weighed.
The residual portion was placed in a tube and the volume was recorded.
Both portions were treated with dithiotreitol (DTT) (Sputolysin; Cal-
biochem Corp., San Diego, CA), freshly prepared in a dilution of one
in 10 with distilled water. The selected portion was treated with a vol-
ume (in microliters) equal to two times the weight of the sputum por-
tion (in milligrams), whereas the residual portion was diluted by a vol-
ume of DTT equal to the volume recorded.
The portions were placed in a shaking water bath at 37
 
8
 
 C for 20
min to ensure complete homogenization. The liquid resulted from se-
lected portions was further diluted with PBS in a volume equal to the
sputum plus DTT. The suspensions were filtered through nylon gauze
to remove mucus and were centrifuged at 1,000 
 
g
 
 for 10 min. The su-
pernatants were aspirated and frozen at 
 
2
 
70
 
8
 
 C for later ECP (
 
m
 
g/L)
analysis by radioimmunoassay (RIA; Kaby Pharmacia Diagnostic
AB, Uppsala, Sweden). The cell pellets were resuspended in PBS. To-
tal cell count (TCC) and viability (Trypan blue exclusion method)
were determined using a Burkers chamber hemocytometer. Cell sus-
pensions were placed in a CYTO-TEK centrifuge (Miles Scientific,
Milan, Italy), and cytospins were prepared at 500 rpm for 6 min.
Cytospin slides were stained with Diff-Quik for overall differential
cell count on 500 (selected sputum) and 200 (residual portion) nucle-
ated nonsquamous cells by two examiners. All sputum counts and
measurements were performed blind to the clinical details. Definition
of an adequate selected sputum was one in which there were fewer
than 20% squamous cells and viability 
 
.
 
 50%.
 
Entire sputum.
 
Sputum was collected and the saliva samples were
processed using method identical to those described by Fahy and col-
leagues (3). In brief, the volume of induced sputum sample and the
samples of saliva were determined, and an equal volume of DTT
(Sputolysin; Calbiochem Corp.), freshly prepared in a dilution of one
in 10 with distilled water, was added. The samples were then placed in
a shaking water bath at 37
 
8
 
 C for 20 min to ensure complete homoge-
nization. At this point the processing was similar to that used for the
residual portion. Definition of an adequate induced sputum sample
was one in which there were fewer than 80% squamous cells on differ-
ential cell count.
 
Statistical Analysis
 
Descriptive statistics were used to summarize clinical and demo-
graphic characteristics of the subjects. Comparison of eosinophils and
ECP in selected and entire sputum are graphically reported as pro-
posed by Bland and Altman (13). Grouped data were reported as
 
TABLE 1
CHARACTERISTICS OF SUBJECTS
 
Asthmatics Healthy Subjects
Subjects, n 18 8
Age, yr* 41 
 
6
 
 17 42 
 
6
 
 17
Sex, male/female 8/10 3/5
Smoking, (ex) 1 (3) 0 (2)
Atopy
 
†
 
12 2
FEV
 
1
 
, % pred* 91 
 
6
 
 21
 
‡
 
119 
 
6 
 
16
FVC, % pred* 103 
 
6
 
 16 112 
 
6 
 
14
PD
 
20
 
 FEV
 
1
 
, 
 
m
 
g
 
§
 
220
 
. 
 
1,600
Inhaled steroid therapy 3
 
2
 
* Values are mean 
 
6
 
 SD.
 
†
 
 Defined as one or more positive allergy skin prick tests.
 
‡
 
 p 
 
,
 
 0.001, significantly different.
 
§
 
 Methacholine PD
 
20
 
 geometric mean.
 
TABLE 2
CELL VIABILITY (%), TOTAL CELL COUNT (
 
3
 
10
 
5
 
/ml), DIFFERENTIAL CELL COUNT (%),
AND ECP (
 
m
 
g/L) IN SELECTED SPUTUM, ENTIRE SPUTUM, AND RESIDUAL
PORTION IN ALL SUBJECTS, HEALTHY SUBJECTS, AND ASTHMATICS*
 
SS
All
Subjects
ES
All
Subjects
RP
All
Subjects
SS
Healthy
Subjects
ES
Healthy
Subjects
RP
Healthy
Subjects
SS
Asthmatics
ES
Asthmatics
RP
Asthmatics
Viability, % 80.6 
 
6
 
 1.6
 
‡¶
 
71.8 
 
6
 
 1.9 70.2 
 
6
 
 2.0 83.0 
 
6
 
 1.9 73.0 
 
6
 
 5.1 69.3 
 
6
 
 4.6 79.5 
 
6
 
 2.1
 
‡¶
 
71.2 
 
6
 
 1.8 70.6 
 
6
 
 2.2
TCC, 
 
3
 
 10
 
5
 
/ml 16.5 
 
6
 
 3.2
 
¶
 
11.1 
 
6
 
 0.9 6.1 
 
6
 
 0.9 13.5 
 
6
 
 5.0
 
i
 
10.9 
 
6
 
 1.5 4.8 
 
6
 
 1.6 18.1 
 
6
 
 4.6
 
¶
 
11.2 
 
6
 
 1.1 6.6 
 
6
 
 1.0
Macro, % 49.9 
 
6
 
 4.8 46.2 
 
6
 
 4.1 48.2 
 
6
 
 4.0 62.6 
 
6
 
 8.1 58.0 
 
6
 
 7.7 55.3 
 
6
 
 8.2 44.3 
 
6
 
 5.6 40.9 
 
6
 
 4.4 45.1 
 
6
 
 4.4
Neutro, % 33.3 
 
6
 
 4.7
 
†
 
i
 
42.7 
 
6
 
 4.3 41.2 
 
6
 
 4.4 34.7 
 
6
 
 8.1 38.0 
 
6
 
 8.3 38.6 
 
6
 
 9.4 32.6 
 
6
 
 5.9
 
†
 
44.9 
 
6
 
 5.1 42.3 
 
6
 
 5.0
Eos, % 15.3 
 
6
 
 4.7
 
†¶
 
8.3 
 
6
 
 3.0 7.7 
 
6
 
 3.0 0.8 
 
6
 
 0.3 0.6 
 
6
 
 0.3 0.6 
 
6
 
 0.2 21.8 
 
6
 
 6.2
 
‡¶
 
11.8 
 
6
 
 4.2 10.9 
 
6
 
 4.1
Lympho, % 0.6 
 
6
 
 0.2 0.6 
 
6
 
 0.2 0.3 
 
6
 
 0.1 0.4 
 
6
 
 0.4 0.4 
 
6
 
 0.3 0.4 
 
6
 
 0.2 0.8 
 
6
 
 0.2 0.7 
 
6
 
 0.3 0.3 
 
6
 
 0.1
Epi cells, % 0.9 
 
6
 
 0.3 2.2 
 
6
 
 0.8 2.6 
 
6
 
 1.0 1.6 
 
6
 
 0.9 3.2 
 
6
 
 2.0 5.2 
 
6
 
 3.1 0.5 
 
6
 
 0.3 1.7 
 
6
 
 0.7 1.4 
 
6
 
 0.5
Sq cells, % 2.7 
 
6
 
 0.6
 
§
 
** 55.6 
 
6
 
 3.1 57.0 
 
6
 
 3.2 2.9 6 0.8‡¶ 62.2 6 3.4 59.3 6 5.8 2.6 6 0.8§** 54.3 6 4.3 56.1 6 3.9
ECP, mg/L 548 6 101§** 105 6 20 74 6 13 180 6 55 40 6 10 28 6 3.3 720 6 123§** 133 6 2.7 91 6 17
Definition of abbreviations: SS 5 selected sputum; ES 5 entire sputum; RP 5 residual portion; TCC 5 total cell count; Macro 5 macrophages; Neutro 5 neutrophils; Eos 5 eosino-
phils, Lympho 5 lymphocytes; Epi cells 5 epithelial cells; Sq cells 5 squamous cells; ECP 5 eosinophil cationic protein.
* Data are expressed as mean and SEM.
† , 0.05, significantly different from entire sputum.
‡ , 0.01, significantly different from entire sputum.
§ , 0.001, significantly different from entire sputum.
i p , 0.05, significantly different from residual portion.
¶ p , 0.01, significantly different from residual portion.
** p , 0.001, significantly different from residual portion.
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arithmetic mean and standard error of the mean (SEM). Based on data
distribution nonparametric tests were used. Differences between se-
lected sputum, entire sputum, and residual portion were assessed by Wil-
coxon’s signed rank test. For data normally distributed (e.g., macro-
phages, neutrophils) differences were assessed by the two-tailed paired
t-test. The comparison between groups (asthmatics versus healthy
subjects) was assessed by the Mann-Whitney U test, p , 0.05 was con-
sidered statistically significant.
RESULTS
The comparisons between selected sputum, entire sputum,
and the residual portion for cell viability (%), total cell count
(3 105/ml), differential cell count (%), and ECP (mg/L) are pre-
sented in Table 2. In brief, the selected sputum contained sig-
nificantly higher cell viability, percentage of eosinophils, and
ECP concentration with respect to entire sputum and residual
portion considering both all subjects or asthmatics only. The
entire expectorate and the residual portion showed a signifi-
cant higher percentage of neutrophils and squamous cells. In
saliva samples, squamous cells were found to constitute 99 6
0.7% of total cells.
With both methods of the selected and entire sputum eosi-
nophils and ECP were found to be significantly higher in asth-
matics than in healthy subjects (Table 3). Comparison of eosi-
nophils and ECP in selected and entire sputum are graphically
reported as proposed by Bland and Altman (Figure 1).
No significant differences for total cells (25.2 6 5 versus
23.8 6 7 3 105/ml), ECP concentration (402 6 75 versus 431 6
69 mg/L), and any cell type were found comparing the two
samples obtained 24 h apart using the same technique (se-
lected sputum) in eight asthmatic subjects (Figure 2).
DISCUSSION
In this study we observed that, as compared with entire spu-
tum, the analysis of selected portions of sputum resulted in an
increased number of eosinophils, viable cells, and in increased
levels of supernatant ECP. By contrast, the percentage of neu-
trophils was higher in the entire sputum. However, we also ob-
served that both methods of analysis have the same diagnostic
value in distinguishing asthmatics from healthy subjects. To our
knowledge this is the first study that has compared the total
and differential cell counts and the levels of ECP in induced
sputum collected on two occasions from asthmatic and healthy
subjects, using two different techniques of processing samples
performed in the same group of subjects.
The increased percentage of eosinophils and the higher
concentration of ECP in selected sputum with respect to the
TABLE 3
EOSINOPHILS (%) AND ECP (mg/L) IN
SELECTED SPUTUM AND IN ENTIRE SPUTUM
Asthmatics
Eos
(SS )
Eos
(ES )
ECP
(SS )
ECP
(ES )
Healthy
Subjects
Eos
(SS )
Eos
(ES )
ECP
(SS )
ECP
(ES )
1 45 44 ND† ND 1 0 0 ND ND
2 75 69 ND ND 2 0 0 12 60
3 4 4 947 180 3 0 0 9 14
4 39 14 1,790 169 4 1 0 185 28
5 8 3 1,151 128 5 2 2 428 74
6 1 1 73 116 6 1 1 150 67
7 5 8 293 48 7 0 0 230 14
8 36 9 1,176 78 8 2 1 248 20
9 25 12 448 136
10 15 4 1,086 400
11 2 1 1,022 314
12 0 0 39 39
13 86 20 ND ND
14 14 8 440 89
15 34 12 800 161
16 0 1 456 91
17 0 1 592 13
18 2 0 492 39
Mean 21.8* 11.8* 720* 133* 0.8 0.6 180 40
SEM 6.2 4.2 123 27 0.3 0.3 55 10
For definition of abbreviations, see Table 2.
* Refers to a significant difference from healthy subjects sputum, p , 0.01.
† Not done.
Figure 1. Bland and Altman plot of eosinophils percentage and
ECP concentration as mean of two values obtained with two differ-
ent methods (entire and selected sputum) compared with the ra-
tio of the value obtained with the selected and entire method.
Asthmatics (closed circles) and healthy subjects (open circles). SD is
standard deviation. n is the number of measures plotted.
Figure 2. Scattegram of cell counts in two selected sputum re-
peated 24 h apart in eight asthmatic subjects (1–8). First day (closed
circles), second day (open circles). Macrophages (Macro), Neutro-
phils (Neutro), Eosinophils (Eosino), Lymphocytes (Lympho), and
Epithelial cells (Epi Cells). Mean and SEM are reported for mac-
rophages and neutrophils.
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entire sputum and residual part may be explained by the ten-
dency of eosinophils to be sequestred in the more viscid por-
tions of the sputum samples. However, the presence of eosino-
phils in the residual part also indicates that if a good selection
of plugs has been done (2% of squamous cells in selected spu-
tum) some inflammatory cells remain in the residual portion
of the sample, as previously described (14).
Compared with selected sputum the percentage of neutro-
phils was higher in the entire sputum. This is unlikely due to
salivary contamination as squamous cells are about 99% of
the cells present in saliva. More likely, the higher percentage
of eosinophils in the selected portion of sputum explain the
lower percentage of neutrophils. If this was the case, “selected
sputum” might underestimate the percentage of neutrophils in
airway secretion of asthmatics, and this should be considered,
particularly for those forms of asthma mainly associated with
sputum neutrophils (e.g., asthma exacerbations caused by vi-
ral infections of the upper airways).
We also found an increased viability of nonsquamous cells
in selected sputum, which might be explained by the capacity
of the mucus to protect the cells from DTT or salivary en-
zymes (15, 16).
Apart from the differences mentioned above between the
selected portion and entire sputum, an important finding of
this study is that both techniques were able to distinguish asth-
matics from healthy subjects in the same group of subjects. Al-
though this data confirms previous reports (1–3, 8), we believe
that the conclusions of our study are stronger because the di-
agnostic value of both methods was demonstrated in the same
group of subjects.
In conclusion, although the selected sputum might under-
estimate the percentage of neutrophils, it is a better method of
analyzing induced sputum, providing more viable cells, more
eosinophils, and higher concentration of ECP in asthmatics.
However, both the selected sputum and the entire sputum
method have the same ability to distinguish asthmatics from
healthy subjects.
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